Takeda Ventures and Alexandria Venture Investments have taken part in a $70m series A round for Ensoma, with Takeda separately signing a strategic collaboration deal.
US-based genomic medicine developer Ensoma launched on Thursday with $70m in series A financing provided by investors including pharmaceutical firm Takeda and life sciences real estate investment trust Alexandria Real Estate Equities. 5AM Ventures led the round, which also included financial services group Fidelity’s F-Prime Capital unit, Viking Global Investors, Cormorant Asset Management, RIT Capital…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.